CRISPR gene editing: Overview
What it does
The job the technology does for people, in a short paragraph
CRISPR gene editing lets scientists change DNA at a chosen place in a living cell. It is used in research laboratories worldwide to study what genes do, to breed crops and, since 2023, in a licensed medicine for two inherited blood disorders [4]. The tool was shown in 2012 and first used in human cells in 2013 [1].
as of 2026-11-11
How it works
The working principle in plain words, step by step
Bacteria defend themselves by storing short pieces of virus DNA in their own genome. They copy these pieces into RNA, which guides a cutting enzyme to any matching virus DNA [1]. Gene editing borrows this system. A short guide RNA is made to match the stretch of DNA to be changed. It joins a Cas enzyme, most often Cas9, which travels along the DNA until the guide finds its match, then cuts both strands [1]. The cell then repairs the break. Repair is often imperfect, which can switch a gene off; it can also copy in new DNA supplied with the tool. In the first licensed medicine, a patient's blood stem cells are edited outside the body and returned, so the body makes working haemoglobin [4].
as of 2026-11-11
Key figures
The handful of numbers that size it up, each with its unit, year and source
| Figure | Value | Unit | Year | Source |
|---|---|---|---|---|
| Sickle cell trial patients free of severe pain crises for at least 12 months | 97 | % (28 of 29) | 2023 | [4] |
| Beta-thalassaemia trial patients free of red cell transfusions for at least 12 months | 93 | % (39 of 42) | 2023 | [4] |
| People with sickle cell disease in the United States, about | 100,000 | people | 2023 | [3] |
| People with sickle cell disorder in the United Kingdom, about | 15,000 | people | 2023 | [4] |
as of 2026-11-11. Trial results are as reported by the UK regulator when it licensed Casgevy in November 2023 [4]; the patient counts are dated by the 2023 FDA and MHRA releases that give them, which state no year of their own [3, 4].
Where it is used
The main places and products the technology is found in
- Research laboratories, to switch genes off and study what they do
- Medicine for sickle cell disease and beta-thalassaemia, licensed in 2023 [4]
- Crop breeding, such as a tomato with more GABA on sale in Japan from 2021 [6, 7]
- Animal and plant research, and the development of further gene therapies
as of 2026-11-11
Scale today
How much of it there is now: units in use, made each year and who uses it
- Users
- One licensed CRISPR medicine by 2023, for two blood disorders, tested in 45 sickle cell and 54 thalassaemia patients [4]
- Unit
- patients
- Year
- 2023
- Note
- No world count of laboratories or edited products was found; the figure counts trial patients for the first medicine only.
as of 2026-11-11
Sources
- A Tool for Genome Editing: Scientific Background on the Nobel Prize in Chemistry 2020 Royal Swedish Academy of Sciences, 2020
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease US Food and Drug Administration, 2023
- MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia Medicines and Healthcare products Regulatory Agency (GOV.UK), 2023
- GABA-enriched tomato is first CRISPR-edited food to enter market Nature Biotechnology
- Japan Starts Sale of Genome-Edited High-GABA Tomato Institute of Agricultural Sciences for Southern Vietnam (news item crediting Sanatech Seed), 2021